Does pentoxifylline enhance the recovery of erectile function after a T-shunt procedure for prolonged ischaemic priapism? A prospective randomised controlled trial

Abdel-Rahman Zahran, Hussein Abdel Daim, Mohamed Youssif *

Department of Urology, Alexandria University, Alexandria, Egypt

Abstract

Objective: To evaluate the role of oral pentoxifylline for enhancing the recovery of erectile function (EF) in patients who had a T-shunt, a technically simple procedure for treating prolonged ischaemic priapism, as the recovery of EF has been reported in many patients treated by this procedure.

Patients and methods: This prospective randomised study was conducted on 40 patients with prolonged ischaemic priapism treated with a T-shunt. Patients were randomly divided into two groups; group A received oral pentoxifylline from the second day after surgery for 3 months, and group B received placebo. Patients were followed for 18 months.

Results: The pain resolved in all patients, and EF recovered in 15 patients in group A and 10 in group B within 3 months. All patients but three had recovery of EF within the 18-month follow-up. Six patients had recovery of EF by using on-demand 50 mg sildenafil. The three patients who did not recover EF had a penile prosthesis implanted after the end of the study.

Conclusion: Pentoxifylline had no significant effect on the recovery of EF after a T-shunt procedure, but a larger study (double-blinded) is required for a more accurate assessment of any beneficial effect of pentoxifylline after a T-shunt procedure.

© 2012 Arab Association of Urology. Production and hosting by Elsevier B.V.
All rights reserved.

* Corresponding author. Address: Paediatric Urology Unit, Department of Urology, University of Alexandria School of Medicine, Alexandria, Egypt. Tel./fax: +20 203 486 0029.
E-mail address: dr.youssif@gmail.com (M. Youssif).
Peer review under responsibility of Arab Association of Urology.
The treatment of ischaemic priapism (IP) is considered a urological emergency [1], because of the associated pain and the structural changes in the penis that can cause penile fibrosis and erectile dysfunction (ED) [2]. Many shunt procedures have been described for managing IP after a failed initial conservative treatment. ED is the most important complication of IP, and the preservation of pre-morbid erectile function (EF) has been reported after shunt procedures, with variable success rates. Brant et al. [3] reported good recovery of EF using the T-shunt procedure.

The aim of the present study was to evaluate the role of oral pentoxifylline for enhancing the recovery of EF in patients who had a T-shunt procedure for IP.

Patients and methods

This prospective randomised study was conducted on 40 patients presenting with prolonged IP. Local ethics committee approval was obtained before conducting the study. All patients signed an informed consent before surgery, explaining the possible outcome of the procedure and approving the use of postoperative oral medication. All 40 patients presented after >24 h of persistent priapism with failed corporeal aspiration and administration of sympathomimetics. None of the patients had any temporary relief of priapism of >10 min with conservative management.

Procedures

Penile cavernous blood-gas analysis and penile Doppler ultrasonography (PDU) were used to confirm the diagnosis of IP. The T-shunt procedure was performed under local anaesthesia (penile block) in all cases. A number 10 blade was used and the technique was performed on one side of the glans, as described by Garcia et al. [4]. If a rigid erection recurred within 20 min from skin closure the procedure was repeated on the other side of the glans. A non-compressive dressing was applied. Patients were instructed to squeeze the penis with their hands regularly during the first 24 h after the shunt. PDU was used in all patients on the first day after surgery. Patients were randomly divided into two groups; group A (20 patients) received oral pentoxifylline 400 mg three times daily with meals for 3 months, starting from the second day after surgery. Group B received a placebo of the same shape, colour and size as the pentoxifylline tablets (sugar-containing tablets) supplied from the Pharmaceutical department of the University.

Follow-up

Patients were followed for 18 months, and assessed using the Sexual Health Inventory for Men (SHIM) score, a questionnaire comprising five questions each having five possible responses scored from 1 to 5. The sum of the answers is calculated to evaluate the EF state; a score of 22–25 denotes no ED. The results were analysed statistically using Student’s t-test, the chi-square test and Fisher’s exact test.

Results

The mean (SD, range) age of the patients was 36.8 (7.3, 24–50) years. The cause of priapism was idiopathic in 18 patients, inappropriate use of intracorporeal vasoactive medication in eight and drug abuse in 14. The duration of priapism was 1–4 days. None of the patients had undergone any previous shunt procedures and the T-shunt was performed as the first option after failed conservative treatment. A bilateral T-shunt was used in 25 patients, 13 in group A and 12 in group B. Intracorporeal tunnelling was performed using a 7-mm diameter straight sound, because of the difficulty of expressing occult blood in five patients (three in group A and two in group B). The pain was resolved in all patients. After 3 months 15 patients in group A had recovery of EF, compared to only 10 in group B, but the difference was not statistically significant (Table 1).

All patients but three had recovery of EF after 18 months of follow-up. Nine patients had pre-existing ED; of these, six had recovery of EF by using on-demand 50 mg sildenafil. Three of these nine did not recover EF throughout the follow-up, even with the use of on-demand 100 mg sildenafil. All three patients had a penile prosthesis implanted after the end of the study.

Discussion

To our knowledge this is the first trial to evaluate the effect of pentoxifylline amongst patients treated after prolonged IP, and the aim was to evaluate its well-known anti-fibrotic effect amongst patients with prolonged IP. The main principle of shunt surgery used for treating IP is the re-establishment of corporeal blood flow, by creating a fistula between the corpus cavernosum and the glans, corpus spongiosum and dorsal or saphenous veins [5–9]. The T-shunt procedure has the advantage of being easy to perform, and with excellent results for treating priapism and a reported good recovery of EF [3].

ED is considered the most important complication of priapism [10]. The outcome of priapism was analysed in 124 cases of previously potent patients by Kulmala et al. [10]. They noted that 39% of their patients became impotent. They also reported a correlation between the duration of symptoms and the risk of priapism [10], where 92% of patients with priapism for <1 day remained potent, whilst potency was preserved in 22% of patients with priapism for >7 days [10]. Nixon et al. [11] reported 90% of patients had ED in their...
follow-up of men who had shunt procedures for low-flow priapism.

Histopathological and molecular studies showed that a long period of anoxia in cases of IP leads to an impairment of smooth muscle contractility and causes smooth muscle cell death and fibrosis of the corpora cavernosa [12]. In addition, hypoxia leads to up-regulation of hypoxia-induced growth factors such as TGF-β, which if present in excess amounts can lead to tissue damage and scarring. Thus it is thought to be an important factor in corporeal tissue fibrosis after prolonged IP [13–15].

Pentoxifylline is a haemorrheological agent (i.e. an agent that affects blood viscosity) with many clinical applications and a high safety profile [16]. Pentoxifylline is now being used by many physicians as a conservative treatment for Peyronie’s disease [16], as it was reported to inhibit fibrosis and TGF-β-mediated collagen deposition in the tunica albuginea [16–18].

Ozdal et al. [19] evaluated the efficacy of using a combined therapy of sildenafil and pentoxifylline to treat vasculogenic ED, and their results suggested that this therapy might be of benefit in treating this condition [19].

Recently, pentoxifylline was used by Albersen et al. [20] to promote the recovery of EF in a rat model with ED after prostatectomy. These authors reported a significant improvement in EF in the group of rats treated with pentoxifylline compared to the control group [20]. They also reported that a histopathological examination of the corpus cavernosum of rats showed that pentoxifylline treatment resulted in a partial restoration of smooth muscle architecture and less collagen deposition than in the control group [20].

The results of the present study showed that patients treated with pentoxifylline had a faster recovery of EF than the control group, although the difference was not statistically significant, probably because there were too few patients in the study, as it was conducted at one institute. The mechanism by which pentoxifylline enhances recovery of EF also needs further assessment, but it might be related to the inhibition of fibrosis and TGF-β-mediated collagen deposition in the tunica.

The advantage of the present study is that it tested a novel idea, i.e. using non invasive measures to promote the recovery of EF after prolonged IP. Despite the well-known beneficial effects of pentoxifylline, i.e. its anti-fibrotic effect [21], the results from the present study would have been more acceptable if it had been double-blinded to avoid any degree of bias. Thus we suggest that a larger multicentre study should be conducted to assess the effect of pentoxifylline after shunt procedures for prolonged IP.

In conclusion, pentoxifylline had no significant effect on the recovery of EF because there were too few patients and the nature of the disease (ischaemic injury rather than fibrosis only), but a larger study (double blinded) is required for a more accurate assessment of any beneficial effect of pentoxifylline after T-shunt procedures.

Conflict of interest
No conflict of interest to declare.

Source of funding
None.

References
[1] Burnett AL, Bivalacqua TJ. Priapism. Current principles and practice. Urol Clin North Am 2007;34:631–42.
[2] Sadeghi-Nejad H, Seftel AD. The etiology, diagnosis, and treatment of priapism: review of the American Foundation for Urologic Disease Consensus Panel Report. Curr Urol Rep 2002;3:492–8.
[3] Brant WM, Garcia MM, Bella AJ, Chi T, Lue TF. T-Shaped shunt and intracavernous tunneling for prolonged ischemic priapism. J Urol 2009;181:1699–705.
[4] Garcia MM, Shinodel AW, Lue TF. T-shunt with or without tunnelling for prolonged ischaemic priapism. BJU Int 2008;102:1754–64.
[5] Lue TF, Pescatori ES. Distal cavernosum-glans shunts for ischemic priapism. J Sex Med 2006;3:749–52.
[6] Winter CC. Cure of idiopathic priapism: new procedure for creating fistula between glans penis and corpora cavernosa. Urology 1976;8:389–91.
[7] Barry JM. Priapism. Treatment with corpus cavernosum to dorsal vein of penis shunts. J Urol 1976;116:754–6.
[8] Quackels R. Treatment of a case of priapism by cavernospongious anastomosis. Acta Urol Belg 1964;32:5–13.
[9] Grayhack JT, McCullough W, O’Connor Jr VJ, Trippel O. Venous bypass to control priapism. Invest Urol 1964;58:509–13.
[10] Kulmala RV, Lehtonen TA, Tammela TL. Preservation of potency after treatment for priapism. Scand J Urol Nephrol 1996;30:313–6.

Table 1 Comparison of the two groups (20 patients each).

| Variable | Group A | Group B | P   |
|----------|---------|---------|-----|
| Mean (SD) |         |         |     |
| Age (years) | 37.9 (7.8) | 35.7 (6.9) | 0.351 |
| Duration of priapism (h) | 36 (19.2) | 31.2 (14.4) | 0.379 |
| SHIM score | 21.2 (1.5) | 18.4 (5.6) | >0.05 |
| Patients with pre-existing ED (n) | 5 | 4 | 0.999 |
| Mean (SD) period for recovery of EF (months) | 3.7 (3.0) | 4.9 (4.1) | 0.298 |
| Patients with recovery of EF after 3 months (n) | 15 | 10 | 0.191 |
| Patients who did not recover EF (n) | 1 | 2 | 0.999 |
[11] Nixon RG, O’Connor JL, Milam DF. Efficacy of shunt surgery for refractory low flow priapism: a report of the incidence of failed detumescence and erectile dysfunction. *J Urol* 2003;170:883–6.

[12] Munarriz R, Park K, Huang YH, Saenz de Tejada I, Moreland I, Goldstein I, et al. Reperfusion of ischemic corporal tissue: physiologic and biochemical changes in an animal model of ischemic priapism. *Urology* 2003;62:760–4.

[13] Jeong WI, Do SH, Yun HS, Song BJ, Kim SJ, Kwak WJ, et al. Hypoxia potentiates transforming growth factor-beta expression of hepatocyte during the cirrhotic condition in rat liver. *Liver Int* 2004;24:658–68.

[14] Bivalacqua TJ, Diner EK, Novak TE, Vohra Y, Sikka SC, Champion HC, et al. A rat model of Peyronie’s disease associated with a decrease in erectile activity and an increase in inducible nitric oxide synthase protein expression. *J Urol* 2000;163:1992–8.

[15] Broderick GA, Kadioglu A, Bivalacqua TJ, Ghanem H, Nehra A, Shamloul R. Priapism: pathogenesis, epidemiology, and management. *J Sex Med* 2010;7:476–84.

[16] Brant WO, Dean RC, Lue TF. Treatment of Peyronie’s disease with oral pentoxifylline. *Nat Clin Pract Urol* 2006;3:111–5.

[17] Lin G, Shindel AW, Banie L, Ning H, Huang YC, Liu G, et al. Pentoxifylline attenuates transforming growth factor-beta1-stimulated elastogenesis in human tunica albuginea-derived fibroblasts part 2. Interference in a TGF-beta1/Smad-dependent mechanism and downregulation of AAT1. *J Sex Med* 2010;7:1787–97.

[18] Shindel AW, Lin G, Ning H, Banie L, Huang YC, Liu G, et al. Pentoxifylline attenuates transforming growth factor-beta1-stimulated collagen deposition and elastogenesis in human tunica albuginea-derived fibroblasts part 1: impact on extracellular matrix. *J Sex Med* 2010;7:2077–85.

[19] Ozdal OL, Ozden C, Gokkaya S, Urgancioglu G, Aktas BK, Memis A. The effect of sildenafil citrate and pentoxifylline combined treatment in the management of erectile dysfunction. *Int Urol Nephrol* 2008;40:133–6.

[20] Albersen M, Fandel TM, Zhang H, Banie L, Lin G, Ridder DD, et al. Pentoxifylline promotes recovery of erectile function in a rat model of postprostatectomy erectile dysfunction. *Eur Urol* 2011;59:286–96.

[21] El Saka AI. Reversion of penile fibrosis: current information and a new horizon. *Arab J Urol* 2011;9:49–55.